Biogen Pharmachem Industries (531752) Q4 13/14 earnings summary

Executive summary

• Sluggish market conditions and financial stress coincided with nil operating revenue and a FY14 net loss of ₹1,301,411; management cited measures to strengthen operations and viability.

• Management expected turnover to improve despite possible recessionary conditions, citing confidence in Indian businesses’ fundamentals.

Financial highlights

• FY14 total expenses were ₹1,301,411, down from ₹1,339,054 in FY13; net loss was ₹1,301,411 versus ₹1,339,054.

• Operating revenue was nil in FY14; other income was nil versus ₹441,181 in FY13.

• Basic and diluted EPS were both reported at -₹0.0020 for FY14 and FY13.

• No dividend was declared due to the annual loss.

Outlook and guidance

• Management expected turnover to improve, despite potential recessionary conditions, based on confidence in Indian businesses’ fundamentals.

• Forward-looking expectations were subject to actual results differing materially from projections and estimates.